<DOC>
	<DOCNO>NCT00413426</DOCNO>
	<brief_summary>This purpose study compare body change blood level single dose darifenacin give 7.5 mg modify release tablet modify release liquid suspension ( 1.5 mg/ml ) fast fed condition healthy subject .</brief_summary>
	<brief_title>Study Compare How Body Changes Blood Level Darifenacin Tablet Form vs. Modified Release Liquid Form Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Healthy , male female subject age 18 50 year age ( inclusive ) In good health Female subject either surgically sterilize least 6 month prior study participation postmenopausal ( regular menstrual bleeding least 2 year ) Body mass index within range 18.5 29.9 kg/m2 weigh least 45 kg Smokers History Urinary retention , narrowangle glaucoma , myasthenia gravis , severe hepatic impairment , severe ulcerative colitis , toxic megacolon Symptomatic hiatus hernia , erosive symptomatic gastroesophageal reflux disease/heartburn ( &gt; 2 day week ) , severe constipation , gastrointestinal obstructive disorder , gastric retention . Clinically significant cardiac abnormality , faint , low blood pressure upon stand , irregular heartbeat Acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease ) Clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) Known hypersensitivity severe adverse event darifenacin similar drug Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize participation study Immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Drug alcohol abuse within 6 month prior dose Use prescription drug within 4 week prior dose , overthecounter medication ( vitamin , herbal supplement , dietary supplement ) within 2 week prior dose . Paracetamol acceptable . Participation clinical investigation within 4 week prior dose Donation loss 400 mL blood within 8 week prior dose . Significant illness within 2 week prior dose . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>oral</keyword>
	<keyword>single dose</keyword>
	<keyword>table</keyword>
	<keyword>suspension</keyword>
	<keyword>release</keyword>
	<keyword>darifenacin</keyword>
	<keyword>healthy subject</keyword>
	<keyword>Healthy volunteer study</keyword>
</DOC>